West Pharmaceutical Services Inc.

Age 50 Director since 2002 Dr. Morel has been Chairman of the Board of the Company since March 2003 and Chief Executive Officer since April 2002. He was President from April 2002 to June 2005, Chief Operating Officer from May 2001 to April 2002, Division President, Drug Delivery Systems from October 1999 to May 2001, and prior thereto, Group President.

Age 61 Director since 2002 Mr. Zenner is the retired President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical manufacturer. Mr. Zenner currently serves as the Interim Chief Executive Officer and a member of the Board of Directors of EXACT Sciences Corporation. He also is a director of ArQule, Inc., CuraGen Corporation, Geron Corporation, Sciele Pharma, Inc. and Xoma Ltd.

In September 2007, Anthony Welters was named president of the Public and Senior Markets Group, which is made up of Ovations and AmeriChoice. He was appointed executive vice president, UnitedHealth Group, in December 2006. Welters had previously been president, chief executive officer and a founder of AmeriChoice, which was acquired by UnitedHealth Group in 2002. Prior to his role with AmeriChoice, Welters held a number of senior positions in the federal government and in private industry.

Chairman of United Rentals and Chief Executive Officer of Structured Ventures; former Executive Officer of several General Electric financial services companies; also a Director of Quest Diagnostics and U.S. - Russia Investment Fund.

John H. Weiland, 51, joined C. R. Bard, Inc. on March 1, 1996. His experience spans over 30 years in the healthcare industry with firms such as Dentsply International, Pharmacia and Baxter Healthcare Corporation. John was named President and Chief Operating Officer of C. R. Bard on August 8, 2003, having worldwide responsibility for all of Bard's business operations. Prior to becoming President and COO, John held the position of Group President of Bard. In this capacity, John had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard's Worldwide Manufacturing Operations. In addition, John also had responsibility for Bard's businesses in Latin America, Mexico, Canada, the Far East and Japan. In 1991, he was named Senior Vice President North America Group for Dentsply International in York, Pennsylvania. This position included general management responsibility for the eleven operating divisions of Dentsply International, the world's leading dental products manufacturer. John graduated from DeSales University with a B.S. degree and earned an M.B.A. degree from New York University. John started his career at Baxter/American Hospital Supply Corporation in 1977 as a sales representative. He rose through numerous managerial positions to become Vice President and General Manager of the Scientific Products Biomedical Division, an 850 million dollar diagnostic division of Baxter. In 1989, he became President and Chief Executive Officer of Pharmacia Diagnostics, a division of Pharmacia AB Upsala Sweden. In this capacity, he had general management responsibility for Pharmacia's three diagnostic businesses. In addition to his professional activities, John is actively involved in civic affairs. In 1987, John was named a White House Fellow and served as a Special Assistant to President Reagan's Cabinet. He is a member of the Board of Directors of Meridian Health System and a Director of West Pharmaceutical Services, Inc.

Age 66 Director since 1989 Mr. Johnson is Managing Partner of Founders Capital Partners, a venture capital angel group. He is Chairman of the Board of HealthBanks Inc. Mr. Johnson is a member of the Corporation of the Massachusetts Institute of Technology and a trustee of the Scholarship Foundation of Santa Barbara.

Lance Willsey, MD has served as a director since May 2000. Dr. Willsey was a founding partner of DCF Capital from July 1998 to April 2002. From July 1997 to July 1998, Dr. Willsey served on the Staff Department of Urologic Oncology at Dana Farber Cancer Institute at Harvard University School of Medicine. From July 1996 to July 1997, Dr. Willsey served on the Staff Department of Urology at Massachusetts General Hospital at Harvard University School of Medicine, where he was a urology resident from July 1992 to July 1996. Dr. Willsey is also a director of Exelixis, Inc. Dr. Willsey holds a BS in physiology from Michigan State University and an MS in biology and an MD from Wayne State University. Patrick J. Zenner has served as a director since March 2003. In January 2001, Mr. Zenner retired from Hoffmann-La Roche Inc., North America, the prescription drug unit of the Roche Group, a leading research-based health care enterprise, where he served as President and Chief Executive Officer since 1993, and was a member of the global Pharmaceutical Executive Committee. Mr. Zenner joined Hoffmann-La Roche Inc. as a sales representative in 1969 and subsequently held a series of marketing and business development posts that culminated in his being named Vice President and General Manager of Roche Laboratories in 1982. He later spent two and a half years with Roche Holding Ltd. as head of international pharmaceutical marketing, development and regulation. In 1988, Mr. Zenner was elected to Hoffmann-La Roche's Executive Committee and Board of Directors, and appointed Senior Vice President of the pharmaceutical division. Mr. Zenner also serves as a director of ArQule, Inc., Curagen Corporation, Dendrite International, Inc., First Horizon Pharmaceuticals Corporation, Genta Inc., Geron Corporation, Praecis Pharmaceuticals, Inc, West Pharmaceutical Services, Inc. and Xoma Ltd. Mr. Zenner holds a BS in business administration from Creighton University and an MBA from Fairleigh Dickinson University and is a Trustee of both universities.

Mr. Federici joined Synvista's Board of Directors in October 2008. He joined West Pharmaceutical Services as Vice President and Chief Financial Officer in August of 2003. Under his financial leadership, West Pharmaceutical has grown its revenues from $300M to over $1B. He was previously National Industry Director for Pharmaceuticals of KPMG LLP (accounting firm) from June 2002 until August 2003, and prior thereto, an audit partner with Arthur Andersen, LLP.

Array